Approximately 20 to 25 participants representing pharma, biotech, academia, and government will come together in July to help define the future of AI in pharmaceutical R&D towards advancing health care in the United States. The specific focus will be to elucidate the opportunities and challenges for AI in drug discovery and development, with a broad view to the scientific, economic, ethical, legal and social aspects …